The call has ended.

Key takeaways

Consolidated revenue ₹7,910 Cr (+29% YoY), EBITDA margin 24%, net profit ₹930 Cr. Growth partly acquisition-led. Saroglitazar launch spend is heavy and the US launch is targeted for March 2027.

Highlights
Revenue growth	+29% YoY consolidated; acquisitions contribute, organic split unstated.
Margins	24% EBITDA; about 150bps higher excluding Saroglitazar launch spend.
Demand visibility	IPM expected to grow 10-11%; branded outperformance of 200-400bps.
Management confidence	Upbeat and repetitive; hedges Keytruda and Saroglitazar timelines.

Growth

Revenue +29% YoY, with acquisitions (Rolvedon via SSHO, Associo) contributing. Organic split not quantified; India branded grew 19% YoY.

Outlook

FY27 EBITDA margin guided at 24%+. Net debt ₹5,200 Cr; management comfortable up to 1x net debt/EBITDA. Saroglitazar FY28 revenue not guided.

Risks

Saroglitazar commercial spend near $100M/yr, with launch timing dependent on FDA queries. Two FDA inspections (SEZ2: 1 observation; Moraya: 5) and a Keytruda biosimilar launch tied to patent litigation.

Last quarter's promises, checked

Delivered

Guided mid-teens India branded growth → delivered 19% YoY (= BEAT)
Guided strong double-digit FY27 revenue growth → delivered +29% YoY, acquisition-aided (= BEAT)

Partly delivered

Guided 300-500bps India outperformance → delivered 200-400bps (= PARTIAL)
Guided 24%+ FY27 EBITDA margin → delivered 24% (= PARTIAL, at floor)
Guided April 2027 Saro launch → targeted March 2027, FDA queries pending (= PARTIAL)

Summary by ALFA Finder, written with AI assistance from the earnings call transcript the company filed, published 4 Nov 2026, 7:16 PM IST. Open it on ALFA Filings ›